OTCM
MEJHY
Market cap7.17bUSD
Oct 08, Last price
13.40USD
1D
0.00%
1Q
19.54%
IPO
-35.14%
Name
Meiji Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Meiji Holdings Co., Ltd., an international enterprise headquartered in Tokyo, Japan, was established in 1916. Through its various subsidiaries, the company specializes in the global manufacturing and distribution of a broad spectrum of products across the food, confectionery, nutritional, and pharmaceutical sectors. Its business activities are distinctly categorized into two core divisions: Food and Pharmaceutical. The Food segment encompasses a wide array of products, including dairy items such as yogurt, cheese, drinking milk, butter, margarine, cream, and ice cream. It also offers various beverages, ready-to-eat meals, and an extensive selection of confectioneries like chocolates, gummy products, and chewing gums. Nutritional offerings within this segment comprise sports nutrition products, infant formula, liquid dietary supplements, and beauty-focused supplements. Additionally, it provides essential ingredients like corn sweeteners and sugar, animal feed, and crucial transportation and distribution services. The Pharmaceutical segment is dedicated to the development and commercialization of medications, including treatments for infectious diseases and central nervous system disorders, alongside a portfolio of generic and over-the-counter (OTC) drugs. This division also serves as a significant provider of human and animal vaccines, blood plasma products, and a range of agricultural and livestock chemicals. For veterinary applications, Meiji offers a comprehensive suite of products for livestock and fisheries, featuring antimicrobial injections, disinfectants, oral medications, insecticides, dewormers, pain relievers, anti-inflammatory agents, hemostatic compounds, and breeding aids. Furthermore, it produces insecticides, metabolites, feed additives, and blended feeds, alongside specialized health solutions for companion animals, such as anesthetics, painkillers, anti-parasitic and gastrointestinal drugs, antibacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements.
Related entities
Subsidiaries
MEDREICH LIMITED
Key people
Jun Hishinuma
Senior Managing Executive Officer, Chief Financial Officer, Director · since 2025
Shinji Matsuoka
Managing Executive Officer, Chief Sustainability Officer · since 2024
Keiko Kawahata
Executive Officer, Manager of Wellness Science Lab · since 2025
Takefumi Koga
Executive Officer · since 2024
Yuhei Matsumoto
Executive Officer, Chief Human Resources Officer, Director of Group Human Resources Strategy · since 2023
Toshiaki Nagasato
Executive Officer , Chief Operating Officer (Pharmaceutical Segment), Director · since 2025
Toshiyasu Sekine
Executive Officer, Chief Human Resources Officer, Director of Human Resources Strategy · since 2025
Youichirou Yamagata
Executive Officer, Director of Business Planning · since 2025
Bunjiro Yao
Executive Officer, Chief Operating Officer (Food Segment), President of Subsidiary, Director · since 2025
Katsunari Matsuda
President, Chief Executive Officer, Representative Director · since 2025
Independent Director · since 2021
Michiko Kuboyama
Independent Director · since 2021
Independent Director · since 2018
Peter Pedersen
Independent Director · since 2022
Headquarters & legal address
中央区京橋2丁目4番16号
東京都, 13 104-0031
JP
東京都, 13 104-0031
JP
Other language
Meiji Holdings Co.Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||